Surrogate therapeutic endpoint for anti-CTLA-4 based immunotherapy of disease

摘要

Provided is the use of an anti-CTLA-4 antibody in the manufacture of a medicament for treating cancer in a patient in need of such treatment, wherein the medicament is formulated for administration according to a dosage regimen sufficient to induce a breakthrough event, wherein the dosage for that regimen has been determined by a procedure whereby the patient has been monitored for the occurrence of a breakthrough event after a measured amount of an anti-CTLA-4 antibody has been administered.